Sanofi says Genzyme won't hit first milestone in CVR deal

07/28/2011 | Reuters

Sanofi said it doesn't expect Genzyme to receive its first milestone fees under a contingent-value right agreement due to the company's inability to resume normal supply of Fabrazyme, one of its key drugs for rare diseases. "To return to normal supply levels of Fabrazyme for existing and new patients, the use of extra capacity at Genzyme's new manufacturing plant in Framingham, Mass., is required," the company announced.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR